GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Days Sales Outstanding

Knight Therapeutics (TSX:GUD) Days Sales Outstanding : 105.12 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Days Sales Outstanding?

Knight Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was C$85.5 Mil. Knight Therapeutics's Revenue for the three months ended in Dec. 2023 was C$74.2 Mil. Hence, Knight Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 105.12.

The historical rank and industry rank for Knight Therapeutics's Days Sales Outstanding or its related term are showing as below:

TSX:GUD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 73.18   Med: 96.62   Max: 341.23
Current: 105.22

During the past 11 years, Knight Therapeutics's highest Days Sales Outstanding was 341.23. The lowest was 73.18. And the median was 96.62.

TSX:GUD's Days Sales Outstanding is ranked worse than
76.82% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs TSX:GUD: 105.22

Knight Therapeutics's Days Sales Outstanding increased from Dec. 2022 (97.75) to Dec. 2023 (105.12).


Knight Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Knight Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Days Sales Outstanding Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 341.23 135.70 88.37 93.42 102.10

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.75 109.63 105.17 104.06 105.12

Competitive Comparison of Knight Therapeutics's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Days Sales Outstanding falls into.



Knight Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Knight Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (94.89 + 88.722) / 2 ) / 328.199*365
=91.806 / 328.199*365
=102.10

Knight Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (82.222 + 88.722) / 2 ) / 74.197*365 / 4
=85.472 / 74.197*365 / 4
=105.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (TSX:GUD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Knight Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines